Liposome-based systems for anti-tumor vaccination: Influence of lipopeptide adjuvants

Journal of Liposome Research

Volumn 16, Issue 3, 2006, Pages 205-213

  Heurtault, Béatrice ^a   Thomann, Jean Sébastien ^a   Jedrzejewska, Justyna ^a   Wels, Winfried S ^b   Schuber, Francis ^a   Frisch, Benoît ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

Author keywords

Adjuvants; Antitumor vaccination; Bioconjugation; Epitopes; ErbB2; Lipopeptides; Liposomes; Peptides

Indexed keywords

ADJUVANT; CYSTEINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; LIPOPEPTIDE; LIPOSOME; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; CANCER CELL; CONFERENCE PAPER; CONJUGATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULARY; IMMUNE RESPONSE; INOCULATION; KIDNEY CARCINOMA; MEMBRANE VESICLE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; AMINO ACID SEQUENCE; ANIMALS; CANCER VACCINES; KIDNEY NEOPLASMS; LIPOSOMES; MICE; MOLECULAR SEQUENCE DATA; PEPTIDES;

EID: 33748496645     PISSN: 08982104     EISSN: 15322394     Source Type: Journal    
DOI: 10.1080/08982100600848736     Document Type: Conference Paper

References (13)

1. Bessler, W. G., Jung, G. (1992). Synthetic lipopeptides as novel adjuvants. Res. Immunol. 143:548-553; discussion 579-580.
2. Gabrilovich, D. (2004). Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat. Rev. Immunol. 4:941-952.
3. Hertz, C. J., Kiertscher, S. M., Godowski, P. J., Bouis, D. A., Norgard, M. V., Roth, M. D., Modlin, R. L. (2001). Microbial lipopeptides stimulate dendritic cell maturation via Toll-like receptor 2. J. Immunol. 166:2444-2450.
4. Knutson, K. L. (2005). Cancer vaccines: The next generation. Drug discov. today. Therapeutic Strategies 2:323-330.
5. Maurer-Gebhard, M., Schmidt, M., Azemar, M., Altenschmidt, U., Stocklin, E., Wels, W., Groner, B. (1998). Systemic treatment with a recombinant erbB-2 receptor-specific tumor toxin efficiently reduces pulmonary metastases in mice injected with genetically modified carcinoma cells. Cancer Res. 58:2661-2666.
6. Roth, A., Espuelas, S., Thumann, C., Frisch, B., Schuber, F. (2004). Synthesis of thiol-reactive lipopeptide adjuvants. Incorporation into liposomes and study of their mitogenic effect on mouse splenocytes. Bioconjug. Chem. 15:541-553.
7. Roth, A., Rohrbach, F., Weth, R., Frisch, B., Schuber, F. Wels, W. S. (2005). Induction of effective and antigen-specific antitumour immunity by a liposomal ErbB2/HER2 peptide-based vaccination construct. Br. J. Cancer 92:1421-1429.
8. Sieling, P. A., Chung, W., Duong, B. T., Godowski, P. J., Modlin, R. L. (2003). Toll-like receptor 2 ligands as adjuvants for human Th1 responses. J. Immunol. 170:194-200.
9. Takeda, K., Takeuchi, O. Akira, S. (2002). Recognition of lipopeptides by Toll-like receptors. J. Endotoxin Res. 8:459-463.
10. Van Der Bruggen, P., Van Den Eynde, B. J. (2006). Processing and presentation of tumor antigens and vaccination strategies. Curr. Opin. Immunol. 18:98-104.
11. Van Der Bruggen, P., Zhang, Y., Chaux, P., Stroobant, V., Panichelli, C., Schultz, E. S., Chapiro, J., Van Den Eynde, B. J., Brasseur, F., Boon, T. (2002). Tumor-specific shared antigenic peptides recognized by human T cells. Immunol. Rev. 188:51-64.
12. Wang, H. Y., Wang, R. F. (2005). Antigen-specific CD4+ regulatory T cells in cancer: implications for immunotherapy. Microbes Infect. 7:1056-1062.
13. Wiesmuller, K. H., Bessler, W., Jung, G. (1983). Synthesis of the mitogenic S-[2,3-bis(palmitoyloxy)propyl]-N-palmitoylpentapeptide from Escherichia coli lipoprotein. Hoppe-Seyler's Z Physiol. Chem. 364:593-606.